Ultragenyx Pharmaceutical Inc. (RARE) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
RARE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RARE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 83.8% | -79.5% | -85.4% |
| 2024 | 86.3% | -95.7% | -101.6% |
| 2023 | 89.6% | -131.1% | -139.7% |
| 2022 | 92.2% | -178.6% | -194.7% |
| 2021 | 95.4% | -108.6% | -129.2% |
Download Data
Export RARE earnings history in CSV or JSON format
Free sign-in required to download data
Ultragenyx Pharmaceutical Inc. (RARE) Earnings Overview
As of May 6, 2026, Ultragenyx Pharmaceutical Inc. (RARE) reported trailing twelve-month net income of -$609M, reflecting +7.3% year-over-year growth. The company earned $-6.06 per diluted share over the past four quarters, with a net profit margin of -85.4%.
Looking at the long-term picture, RARE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2011.
Ultragenyx Pharmaceutical Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BMRN ($269M net income, 10.8% margin), SRPT ($65M net income, -32.5% margin), IONS (-$327M net income, -40.4% margin), RARE has room to improve margins relative to the peer group. Compare RARE vs BMRN →
RARE Earnings vs Peers
Earnings metrics vs comparable public companies
RARE Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$575M | -1.0% | -$535M | $-5.83 | -85.4% | -79.5% |
| 2024 | -$569M | +6.2% | -$536M | $-6.29 | -101.6% | -95.7% |
| 2023 | -$607M | +14.2% | -$569M | $-8.25 | -139.7% | -131.1% |
| 2022 | -$707M | -55.8% | -$649M | $-10.12 | -194.7% | -178.6% |
| 2021 | -$454M | -143.4% | -$382M | $-6.70 | -129.2% | -108.6% |
| 2020 | -$187M | +53.7% | -$330M | $-3.07 | -68.8% | -121.8% |
| 2019 | -$403M | -103.8% | -$424M | $-7.12 | -388.3% | -409.0% |
| 2018 | -$198M | +34.6% | -$371M | $-3.97 | -383.7% | -721.2% |
| 2017 | -$302M | -22.9% | -$329M | $-7.12 | -11567.3% | -12593.5% |
| 2016 | -$246M | -68.8% | -$248M | $-6.21 | -184867.7% | -186471.4% |
See RARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RARE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RARE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRARE — Frequently Asked Questions
Quick answers to the most common questions about buying RARE stock.
Is RARE growing earnings?
RARE EPS stands at $-6.06, with +7.3% growth matching the 5-year CAGR of N/A. TTM net income is $-609M. Earnings trajectory remains consistent.
What are RARE's profit margins?
Ultragenyx Pharmaceutical Inc. net margin is -85.4%, with operating margin at -79.5%. Below-average margins reflect competitive or cost pressures.
How consistent are RARE's earnings?
RARE earnings data spans 2011-2025. The current earnings trend is +7.3% YoY. Historical data enables comparison across business cycles.